Search Results - "Ektare, V"
-
1
Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting
Published in Journal of medical economics (01-01-2015)“…To estimate, from a US payer perspective, the cost offsets of treating gram positive acute bacterial skin and skin-structure infections (ABSSSI) with varied…”
Get more information
Journal Article -
2
Cost impact of depofoam bupivacaine for the management of post-surgical pain
Published in Value in health (01-05-2013)Get full text
Journal Article -
3
-
4
Short-term economic and clinical outcomes of canagliflozin compared to sitagliptin in the management of type 2 diabetes mellitus (t2dm)
Published in Value in health (01-05-2014)Get full text
Journal Article -
5
-
6
-
7
EE272 Cost-Effectiveness of Voclosporin in Combination with Mycophenolate Mofetil for Active Lupus Nephritis in Sweden
Published in Value in health (01-12-2023)Get full text
Journal Article -
8
-
9
PBI7 BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
Published in Value in health (01-05-2020)Get full text
Journal Article -
10
PCV21 Cost-Effectiveness of Atorvastatin Versus Simvastatin in Prevention of Cardiovascular Events from a Thailand Societal Perspective
Published in Value in health (01-06-2021)Get full text
Journal Article -
11
PBI17 BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
Published in Value in health (01-05-2020)Get full text
Journal Article -
12
PBI6 ECONOMIC MODEL OF COST SAVINGS WITH TRASTUZUMAB-QYYP (BIOSIMILAR TRASTUZUMAB) FROM THE FRENCH BUYER AND PAYER PERSPECTIVES
Published in Value in health (01-05-2020)Get full text
Journal Article -
13
Cost-Effectiveness Analysis of Continuous Versus Intermittent Celecoxib Use for HIP and Knee Osteoarthritis
Published in Value in health (01-10-2017)“…OBJECTIVES: Intermittent celecoxib use reduces drug cost and limits risk of adverse events, but mitigates drug efficacy. The objective of this study was to…”
Get full text
Journal Article -
14
PMS51 - Cost-Effectiveness Analysis of Continuous Versus Intermittent Celecoxib Use for HIP and Knee Osteoarthritis
Published in Value in health (01-10-2017)Get full text
Journal Article -
15
PSY37 - Cost impact of depofoam bupivacaine for the management of post-surgical pain
Published in Value in health (01-05-2013)Get full text
Journal Article -
16
PSY71 - Cost-Effectiveness of Apremilast In Moderate-To-Severe Psoriasis In Canada
Published in Value in health (01-11-2016)Get full text
Journal Article -
17
Cost-Effectiveness of Apremilast In Moderate-To-Severe Psoriasis In Canada
Published in Value in health (01-11-2016)Get full text
Journal Article -
18
-
19
PDB77 - Short-term economic and clinical outcomes of canagliflozin compared to sitagliptin in the management of type 2 diabetes mellitus (t2dm)
Published in Value in health (01-05-2014)Get full text
Journal Article -
20